Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...
Medicaid expansion under the Affordable Care Act (ACA) significantly increased the number of people at risk of HIV diagnosis ...
Rutgers Health researchers found that prescription rates for preexposure prophylaxis rose overall, but racial disparities ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback